PF-08046054

PF-08046054 (SGN-PDL1V) is a PD-L1-directed antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to the vedotin drug-linker, VcMMAE (HY-15575) . PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors[1].

Product Specifications

Product Name Alternative

SGN-PDL1V

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin; PD-1/PD-L1

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

97.41

Smiles

[PF-08046054]

Molecular Weight

150166 (average)

References & Citations

[1]Byron Kwan, et al. 783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors Free. Regular and Young Investigator Award Abstracts. Immuno-Conjugates and Chimeric Molecules.